Wednesday, June 10, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 116 of 200 Β· By data quality, then INN

  1. aducanumab

    ADUHELM

    EMA: application withdrawn

    N07
  2. agomelatine

    VALDOXAN

    EMA: approved

    N06AX22
  3. albutrepenonacog alfa

    IDELVION

    EMA: approved Β· PMDA: approved

    B02BD04
  4. alectinib

    ALECENSA Hoffmann-La Roche

    EMA: approved Β· TGA: approved Β· NMPA: clinical trials

    L01ED03
  5. alendronate sodium trihydrate

    ALENDRONIC ACID / COLECALCIFEROL MYLAN

    EMA: application withdrawn

    M05BB03
  6. alendronic acid

    VANTAVO (PREVIOUSLY ALENDRONATE SODIUM AND COLECALCIFEROL, MSD)

    EMA: approved

    M05BB03
  7. alipogene tiparvovec

    GLYBERA

    EMA: unknown

    C10AX10
  8. allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (Ξ΄lngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)

    ZALMOXIS

    EMA: withdrawn

    L01
  9. allogeneic umbilical cord-derived cd34- cells, non-expanded

    ZEMCELPRO

    EMA: approved

    B05AX04
  10. alpha-1-antitrypsin

    INFINIA

    EMA: application withdrawn

    B02AB02
  11. alpha1-proteinase inhibitor (human)

    RESPREEZA

    EMA: approved

    B02AB02
  12. amikacin

    ARIKAYCE LIPOSOMAL

    EMA: approved

    J01GB06
  13. amivantamab

    RYBREVANT Janssen-Cilag Pty Ltd

    EMA: approved Β· TGA: approved Β· PMDA: approved

    L01FX18
  14. amlodipine

    AMLO 10 Alphapharm Pty Ltd

    EMA: approved Β· TGA: approved

    C09DX01
  15. amlodipine besilate

    EXFORGE HCT

    EMA: approved

    C09DX01
  16. anamorelin

    ADLUMIZ

    EMA: refused

    V03
  17. andexanet alfa

    ONDEXXYA

    EMA: approved

    V03AB
  18. anecortave acetate

    RETAANE

    EMA: application withdrawn

  19. angiotensin ii

    GIAPREZA

    EMA: approved

    C09
  20. anifrolumab

    SAPHNELO AstraZeneca

    EMA: approved Β· TGA: approved

    L04AG11
  21. anti-melanoma mab fragments

    TECNEMAB K1

    EMA: withdrawn

    V09IA02
  22. antithrombin alfa

    ATRYN

    EMA: withdrawn

    B01AB02
  23. arachis hypogaea extract

    ABYLQIS

    EMA: application withdrawn

    V01AA08
  24. arcitumomab

    CEA-SCAN

    EMA: withdrawn

    V09IA01

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.